Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

neoantigen heat shock protein vaccine rHSC-DIPGVax

An off-the-shelf (OTS) peptide-based cancer vaccine consisting of sixteen heat shock protein (Hsp) neo-epitopes that are found in the majority of diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG) tumors, with potential immunomodulating and antineoplastic activities. Upon administration of the neoantigen Hsp vaccine rHSC-DIPGVax, the peptides stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the Hsp neo-epitopes, which results in tumor cell lysis. Hsps are overexpressed in a variety of tumor cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Hsp vaccine rHSC-DIPGVax
neoantigen Hsp vaccine rHSC-DIPGVax
rHSC-DIPGVax
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search